{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:17Z","timestamp":1793939417469,"version":"4.8.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00415-023-11737-8","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T07:01:57Z","timestamp":1683529317000},"page":"4132-4150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-7033","authenticated-orcid":false,"given":"Abdullah","family":"Al-Ani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"11737_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00234-007-0216-2","volume":"49","author":"AR Ca\u00f1ellas","year":"2007","unstructured":"Ca\u00f1ellas AR, Gols AR, Izquierdo JR et al (2007) Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 49:393\u2013409. https:\/\/doi.org\/10.1007\/s00234-007-0216-2","journal-title":"Neuroradiology"},{"key":"11737_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1212\/CON.0000000000001168","volume":"28","author":"F Costello","year":"2022","unstructured":"Costello F (2022) Neuromyelitis optica spectrum disorders. Contin Lifelong Learn Neurol 28:1131\u20131170. https:\/\/doi.org\/10.1212\/CON.0000000000001168","journal-title":"Contin Lifelong Learn Neurol"},{"key":"11737_CR3","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1212\/CON.0000000000001127","volume":"28","author":"E Longbrake","year":"2022","unstructured":"Longbrake E (2022) Myelin oligodendrocyte glycoprotein-associated disorders. Contin Lifelong Learn Neurol 28:1171\u20131193. https:\/\/doi.org\/10.1212\/CON.0000000000001127","journal-title":"Contin Lifelong Learn Neurol"},{"key":"11737_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20:762\u2013772. https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"11737_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"11737_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"11737_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","volume":"22","author":"JL Bennett","year":"2023","unstructured":"Bennett JL, Costello F, Chen JJ et al (2023) Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 22:89\u2013100. https:\/\/doi.org\/10.1016\/S1474-4422(22)00187-9","journal-title":"Lancet Neurol"},{"key":"11737_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","volume":"136","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Tobin WO, Majed M et al (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4\u2013IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136:419. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.6757","journal-title":"JAMA Ophthalmol"},{"key":"11737_CR9","doi-asserted-by":"publisher","unstructured":"Chen JJ, Flanagan EP, Bhatti MT, et al (2022) Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord 68:104237. https:\/\/doi.org\/10.1016\/j.msard.2022.104237","DOI":"10.1016\/j.msard.2022.104237"},{"key":"11737_CR10","doi-asserted-by":"publisher","unstructured":"Vosoughi AR, Muccilli A, Schneider R, et al (2022) Recovery of Vision in Myelin Oligodendrocyte Glycoprotein\u2013IgG Optic Neuritis Without Treatment: A Case Series. J Neuro-Ophthalmology Publish Ah:3\u20135. https:\/\/doi.org\/10.1097\/WNO.0000000000001583","DOI":"10.1097\/WNO.0000000000001583"},{"key":"11737_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(20)30392-6","journal-title":"Lancet Neurol"},{"key":"11737_CR12","doi-asserted-by":"publisher","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","volume":"97","author":"E Sechi","year":"2021","unstructured":"Sechi E, Krecke KN, Messina SA et al (2021) Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology 97:e1097\u2013e1109. https:\/\/doi.org\/10.1212\/WNL.0000000000012467","journal-title":"Neurology"},{"key":"11737_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121\u2013127. https:\/\/doi.org\/10.1002\/ana.1032","journal-title":"Ann Neurol"},{"key":"11737_CR14","doi-asserted-by":"publisher","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 13:885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218","DOI":"10.3389\/fneur.2022.885218"},{"key":"11737_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/nejm199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581\u2013588. https:\/\/doi.org\/10.1056\/nejm199202273260901","journal-title":"N Engl J Med"},{"key":"11737_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"11737_CR17","doi-asserted-by":"publisher","unstructured":"Gait\u00e1n MI, Paday Formenti ME, Calandri I, et al (2022) The central vein sign is present in most infratentorial multiple sclerosis plaques. Mult Scler Relat Disord 58:103484. https:\/\/doi.org\/10.1016\/j.msard.2021.103484","DOI":"10.1016\/j.msard.2021.103484"},{"key":"11737_CR18","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1212\/CON.0000000000000783","volume":"25","author":"F Costello","year":"2019","unstructured":"Costello F, Scott JN (2019) Imaging in Neuro-ophthalmology. Contin Lifelong Learn Neurol 25:1438\u20131490. https:\/\/doi.org\/10.1212\/CON.0000000000000783","journal-title":"Contin Lifelong Learn Neurol"},{"key":"11737_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/nop\/npw006","volume":"4","author":"KA Myers","year":"2017","unstructured":"Myers KA, Nikolic A, Romanchuk K et al (2017) Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency. Neuro-Oncology Pract 4:60\u201366. https:\/\/doi.org\/10.1093\/nop\/npw006","journal-title":"Neuro-Oncology Pract"},{"key":"11737_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s13365-021-00986-w","volume":"27","author":"RMC Abrams","year":"2021","unstructured":"Abrams RMC, Safavi F, Tuhrim S et al (2021) MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis? J Neurovirol 27:650\u2013655. https:\/\/doi.org\/10.1007\/s13365-021-00986-w","journal-title":"J Neurovirol"},{"key":"11737_CR21","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/brain\/awx200","volume":"140","author":"WO Tobin","year":"2017","unstructured":"Tobin WO, Guo Y, Krecke KN et al (2017) Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 140:2415\u20132425. https:\/\/doi.org\/10.1093\/brain\/awx200","journal-title":"Brain"},{"key":"11737_CR22","doi-asserted-by":"publisher","unstructured":"Guo J, Bu Y, Liu W (2022) Case Report: A Case With MOGAD and Anti-NMDAR Encephalitis Overlapping Syndrome Mimicing Radiological Characteristics of CLIPPERS. Front Immunol 13:832084. https:\/\/doi.org\/10.3389\/fimmu.2022.832084","DOI":"10.3389\/fimmu.2022.832084"},{"key":"11737_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","volume":"92","author":"SA Banks","year":"2021","unstructured":"Banks SA, Morris PP, Chen JJ et al (2021) Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 92:384\u2013390. https:\/\/doi.org\/10.1136\/jnnp-2020-325121","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11737_CR24","doi-asserted-by":"crossref","unstructured":"Pike M (2013) Opsoclonus\u2013myoclonus syndrome. In: Handbook of Clinical Neurology. Elsevier, pp 1209\u20131211","DOI":"10.1016\/B978-0-444-52910-7.00042-8"},{"key":"11737_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jamaophthalmol.2017.5470","volume":"136","author":"L Stunkel","year":"2018","unstructured":"Stunkel L, Kung NH, Wilson B et al (2018) Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol 136:76. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.5470","journal-title":"JAMA Ophthalmol"},{"key":"11737_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0000000000008786","volume":"94","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Krecke KN, Flanagan EP et al (2020) Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG\u2013associated disorders (MOGAD)? Neurology 94:85\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000008786","journal-title":"Neurology"},{"key":"11737_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578083","author":"J Jonathan Maran","year":"2023","unstructured":"Jonathan Maran J, Sharpe C, Carroll S (2023) Journal Pre-proof Paediatric MOG-antibody disease presenting with intracranial hypertension and unilateral vision loss without radiological evidence of optic neuritis. J Neuroimmunol. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578083","journal-title":"J Neuroimmunol"},{"key":"11737_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1352458518804127","volume":"25","author":"R Marignier","year":"2019","unstructured":"Marignier R (2019) Unusual presentations of MOG antibody-associated central nervous system demyelination: expanding the spectrum. Mult Scler J 25:128\u2013129. https:\/\/doi.org\/10.1177\/1352458518804127","journal-title":"Mult Scler J"},{"key":"11737_CR29","doi-asserted-by":"publisher","unstructured":"Valdrighi A, Russ J, Waubant E, et al (2021) Atypical myelin oligodendrocyte glycoprotein antibody disease presenting with isolated elevated intracranial pressure. Neuroimmunol Reports 1:100028. https:\/\/doi.org\/10.1016\/j.nerep.2021.100028","DOI":"10.1016\/j.nerep.2021.100028"},{"key":"11737_CR30","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/bjophthalmol-2020-317267","volume":"105","author":"AR Vosoughi","year":"2021","unstructured":"Vosoughi AR, Ling J, Tam KT et al (2021) Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. Br J Ophthalmol 105:1591\u20131598. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317267","journal-title":"Br J Ophthalmol"},{"key":"11737_CR31","doi-asserted-by":"publisher","unstructured":"Costello F (2014) Inflammatory optic neuropathies. Continuum (Minneap Minn) 20:816\u201337. https:\/\/doi.org\/10.1212\/01.CON.0000453316.60013.52","DOI":"10.1212\/01.CON.0000453316.60013.52"},{"key":"11737_CR32","doi-asserted-by":"publisher","unstructured":"Reindl M, Schanda K, Woodhall M, et al (2020) International multicenter examination of MOG antibody assays. Neurol\u2014Neuroimmunol Neuroinflammation 7:e674. https:\/\/doi.org\/10.1212\/NXI.0000000000000674","DOI":"10.1212\/NXI.0000000000000674"},{"key":"11737_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","volume":"78","author":"E Sechi","year":"2021","unstructured":"Sechi E, Buciuc M, Pittock SJ et al (2021) Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 78:741. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0912","journal-title":"JAMA Neurol"},{"key":"11737_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.947630","volume":"13","author":"GS Manzano","year":"2022","unstructured":"Manzano GS, Salky R, Mateen FJ et al (2022) Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort. Front Neurol 13:1\u20134. https:\/\/doi.org\/10.3389\/fneur.2022.947630","journal-title":"Front Neurol"},{"key":"11737_CR35","doi-asserted-by":"publisher","unstructured":"Benard-seguin E, Costello F (2023) Optic neuritis\u202f: current challenges in diagnosis and management. 36:10\u201318. https:\/\/doi.org\/10.1097\/WCO.0000000000001128","DOI":"10.1097\/WCO.0000000000001128"},{"key":"11737_CR36","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","volume":"100","author":"S Carta","year":"2023","unstructured":"Carta S, Cobo Calvo \u00c1, Armangu\u00e9 T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF. Neurology 100:e1095\u2013e1108. https:\/\/doi.org\/10.1212\/WNL.0000000000201662","journal-title":"Neurology"},{"key":"11737_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.866824","volume":"13","author":"A Dinoto","year":"2022","unstructured":"Dinoto A, Sechi E, Flanagan EP et al (2022) Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease. Front Neurol 13:1\u201313. https:\/\/doi.org\/10.3389\/fneur.2022.866824","journal-title":"Front Neurol"},{"key":"11737_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","volume":"93","author":"S Pace","year":"2022","unstructured":"Pace S, Orrell M, Woodhall M et al (2022) Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry 93:334\u2013335. https:\/\/doi.org\/10.1136\/jnnp-2021-326779","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11737_CR39","doi-asserted-by":"publisher","unstructured":"Kwon YN, Kim B, Kim J-S, et al (2022) Myelin Oligodendrocyte glycoprotein-immunoglobulin G in the CSF. Neurol\u2014Neuroimmunol Neuroinflammation 9:e1095. https:\/\/doi.org\/10.1212\/NXI.0000000000001095","DOI":"10.1212\/NXI.0000000000001095"},{"key":"11737_CR40","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","volume":"93","author":"S Mariotto","year":"2019","unstructured":"Mariotto S, Gajofatto A, Batzu L et al (2019) Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 93:e1867\u2013e1872. https:\/\/doi.org\/10.1212\/WNL.0000000000008479","journal-title":"Neurology"},{"key":"11737_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaneurol.2019.3656","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Chen JJ, McKeon A et al (2020) Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol 77:257. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3656","journal-title":"JAMA Neurol"},{"key":"11737_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/WNO.0000000000001772","volume":"43","author":"M Lerch","year":"2023","unstructured":"Lerch M, Bauer A, Reindl M (2023) The Potential pathogenicity of myelin oligodendrocyte glycoprotein antibodies in the optic pathway. J Neuro-Ophthalmology 43:5\u201316. https:\/\/doi.org\/10.1097\/WNO.0000000000001772","journal-title":"J Neuro-Ophthalmology"},{"key":"11737_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3174\/ajnr.A4539","volume":"37","author":"A Traboulsee","year":"2016","unstructured":"Traboulsee A, Simon JH, Stone L et al (2016) Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol 37:394\u2013401. https:\/\/doi.org\/10.3174\/ajnr.A4539","journal-title":"Am J Neuroradiol"},{"key":"11737_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O et al (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56\u201366. https:\/\/doi.org\/10.1016\/j.neuron.2016.05.018","journal-title":"Neuron"},{"key":"11737_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"11737_CR46","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jnc.15549","volume":"160","author":"W Luo","year":"2022","unstructured":"Luo W, Chen Y, Mao S et al (2022) Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: Correlation with relapses and seizures. J Neurochem 160:568\u2013577. https:\/\/doi.org\/10.1111\/jnc.15549","journal-title":"J Neurochem"},{"key":"11737_CR47","doi-asserted-by":"publisher","unstructured":"Chang X, Huang W, Wang L, et al (2021) Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Front Immunol 12:647618. https:\/\/doi.org\/10.3389\/fimmu.2021.647618","DOI":"10.3389\/fimmu.2021.647618"},{"key":"11737_CR48","doi-asserted-by":"publisher","unstructured":"Kim H, Lee E-J, Kim S, et al (2020) Serum biomarkers in myelin oligodendrocyte glycoprotein antibody\u2013associated disease. Neurol\u2014Neuroimmunol Neuroinflammation 7:e708. https:\/\/doi.org\/10.1212\/NXI.0000000000000708","DOI":"10.1212\/NXI.0000000000000708"},{"key":"11737_CR49","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/acn3.51234","volume":"7","author":"C Barro","year":"2020","unstructured":"Barro C, Chitnis T, Weiner HL (2020) Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol 7:2508\u20132523. https:\/\/doi.org\/10.1002\/acn3.51234","journal-title":"Ann Clin Transl Neurol"},{"key":"11737_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00415-020-10352-1","volume":"269","author":"LB De Lott","year":"2022","unstructured":"De Lott LB, Bennett JL, Costello F (2022) The changing landscape of optic neuritis: a narrative review. J Neurol 269:111\u2013124. https:\/\/doi.org\/10.1007\/s00415-020-10352-1","journal-title":"J Neurol"},{"key":"11737_CR51","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ana.26440","volume":"92","author":"FC Oertel","year":"2022","unstructured":"Oertel FC, Sotirchos ES, Zimmermann HG et al (2022) Longitudinal retinal changes in <scp>MOGAD<\/scp>. Ann Neurol 92:476\u2013485. https:\/\/doi.org\/10.1002\/ana.26440","journal-title":"Ann Neurol"},{"key":"11737_CR52","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/WNO.0000000000001116","volume":"41","author":"J Yu","year":"2021","unstructured":"Yu J, Huang Y, Quan C et al (2021) Alterations in the retinal vascular network and structure in MOG antibody-associated disease: an optical coherence tomography angiography study. J Neuro-Ophthalmology 41:e424\u2013e432. https:\/\/doi.org\/10.1097\/WNO.0000000000001116","journal-title":"J Neuro-Ophthalmology"},{"key":"11737_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12883-022-02848-2","volume":"22","author":"Y Yao","year":"2022","unstructured":"Yao Y, Li X, Xu Y et al (2022) The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON. BMC Neurol 22:323. https:\/\/doi.org\/10.1186\/s12883-022-02848-2","journal-title":"BMC Neurol"},{"key":"11737_CR54","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266:1280\u20131286. https:\/\/doi.org\/10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"11737_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","volume":"21","author":"Y Hacohen","year":"2019","unstructured":"Hacohen Y, Banwell B (2019) Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 21:2. https:\/\/doi.org\/10.1007\/s11940-019-0541-x","journal-title":"Curr Treat Options Neurol"},{"key":"11737_CR56","doi-asserted-by":"publisher","unstructured":"Jarius S, Ruprecht K, Kleiter I, et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0","DOI":"10.1186\/s12974-016-0718-0"},{"key":"11737_CR57","doi-asserted-by":"publisher","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, et al (2019) Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol\u2014Neuroimmunol Neuroinflammation 6:e572. https:\/\/doi.org\/10.1212\/NXI.0000000000000572","DOI":"10.1212\/NXI.0000000000000572"},{"key":"11737_CR58","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ane.13004","volume":"138","author":"K Soelberg","year":"2018","unstructured":"Soelberg K, Specovius S, Zimmermann HG et al (2018) Optical coherence tomography in acute optic neuritis: a population-based study. Acta Neurol Scand 138:566\u2013573. https:\/\/doi.org\/10.1111\/ane.13004","journal-title":"Acta Neurol Scand"},{"key":"11737_CR59","doi-asserted-by":"publisher","unstructured":"Rode J, Pique J, Maarouf A, et al (2022) Time to steroids impacts visual outcome of optic neuritis in MOGAD. J Neurol Neurosurg Psychiatry jnnp-2022\u2013330360. https:\/\/doi.org\/10.1136\/jnnp-2022-330360","DOI":"10.1136\/jnnp-2022-330360"},{"key":"11737_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/WNO.0000000000001684","volume":"42","author":"BK Chwalisz","year":"2022","unstructured":"Chwalisz BK, Levy M (2022) The treatment of myelin oligodendrocyte glycoprotein antibody disease: a state-of-the-art review. J Neuro-Ophthalmology 42:292\u2013296. https:\/\/doi.org\/10.1097\/WNO.0000000000001684","journal-title":"J Neuro-Ophthalmology"},{"key":"11737_CR61","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","volume":"267","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Karthikeayan V, Gibbons E et al (2020) Treatment of MOG antibody associated disorders: results of an international survey. J Neurol 267:3565\u20133577. https:\/\/doi.org\/10.1007\/s00415-020-10026-y","journal-title":"J Neurol"},{"key":"11737_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cen3.12630","volume":"12","author":"S Healy","year":"2021","unstructured":"Healy S, Elhadd KT, Gibbons E et al (2021) Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G\u2013associated disease. Clin Exp Neuroimmunol 12:22\u201341. https:\/\/doi.org\/10.1111\/cen3.12630","journal-title":"Clin Exp Neuroimmunol"},{"key":"11737_CR63","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","volume":"75","author":"SA Morrow","year":"2018","unstructured":"Morrow SA, Fraser JA, Day C et al (2018) Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids. JAMA Neurol 75:690. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0024","journal-title":"JAMA Neurol"},{"key":"11737_CR64","doi-asserted-by":"publisher","unstructured":"Ramanathan sudarshini, Mohammad S, Tantsis E, et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89:127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","DOI":"10.1136\/jnnp-2017-316880"},{"key":"11737_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4015075","volume":"2019","author":"H Song","year":"2019","unstructured":"Song H, Zhou H, Yang M et al (2019) Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol 2019:1\u20137. https:\/\/doi.org\/10.1155\/2019\/4015075","journal-title":"J Ophthalmol"},{"key":"11737_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11910-019-1014-z","volume":"19","author":"DA Tajfirouz","year":"2019","unstructured":"Tajfirouz DA, Bhatti MT, Chen JJ (2019) Clinical characteristics and treatment of MOG-IgG\u2013associated optic neuritis. Curr Neurol Neurosci Rep 19:100. https:\/\/doi.org\/10.1007\/s11910-019-1014-z","journal-title":"Curr Neurol Neurosci Rep"},{"key":"11737_CR67","doi-asserted-by":"publisher","unstructured":"Huda S, Whittam D, Jackson R, et al (2021) Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open 11:e055392. https:\/\/doi.org\/10.1136\/bmjopen-2021-055392","DOI":"10.1136\/bmjopen-2021-055392"},{"key":"11737_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/practneurol-2019-002336","volume":"20","author":"C Osman","year":"2020","unstructured":"Osman C, Jennings R, El-Ghariani K, Pinto A (2020) Plasma exchange in neurological disease. Pract Neurol 20:92\u201399. https:\/\/doi.org\/10.1136\/practneurol-2019-002336","journal-title":"Pract Neurol"},{"key":"11737_CR69","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2016) Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206\u2013216. https:\/\/doi.org\/10.1002\/ana.24554","journal-title":"Ann Neurol"},{"key":"11737_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1744-9987.12067","volume":"18","author":"AA Sokolov","year":"2014","unstructured":"Sokolov AA, Solovyev AG (2014) Russian pioneers of therapeutic hemapheresis and extracorporeal hemocorrection: 100-year anniversary of the world\u2019s first successful plasmapheresis. Ther Apher Dial 18:117\u2013121. https:\/\/doi.org\/10.1111\/1744-9987.12067","journal-title":"Ther Apher Dial"},{"key":"11737_CR71","doi-asserted-by":"publisher","unstructured":"Levy M (2018) Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurol - Neuroimmunol Neuroinflammation 5:e510. https:\/\/doi.org\/10.1212\/NXI.0000000000000510","DOI":"10.1212\/NXI.0000000000000510"},{"key":"11737_CR72","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0140-6736(76)91917-6","volume":"2","author":"AJ Pinching","year":"1976","unstructured":"Pinching AJ, Peters DK (1976) Remission of myasthenia gravis following plasma-exchange. Lancet (London, England) 2:1373\u20131376. https:\/\/doi.org\/10.1016\/s0140-6736(76)91917-6","journal-title":"Lancet (London, England)"},{"key":"11737_CR73","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.transci.2017.08.013","volume":"56","author":"S Oji","year":"2017","unstructured":"Oji S, Nomura K (2017) Immunoadsorption in neurological disorders. Transfus Apher Sci 56:671\u2013676. https:\/\/doi.org\/10.1016\/j.transci.2017.08.013","journal-title":"Transfus Apher Sci"},{"key":"11737_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jca.21324","volume":"30","author":"M Kobayashi","year":"2015","unstructured":"Kobayashi M, Nanri K, Taguchi T et al (2015) Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase. J Clin Apher 30:43\u201345. https:\/\/doi.org\/10.1002\/jca.21324","journal-title":"J Clin Apher"},{"key":"11737_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1756285616646332","volume":"9","author":"S Faissner","year":"2016","unstructured":"Faissner S, Nikolayczik J, Chan A et al (2016) Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 9:281\u2013286. https:\/\/doi.org\/10.1177\/1756285616646332","journal-title":"Ther Adv Neurol Disord"},{"key":"11737_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.02.013","author":"JJ Chen","year":"2023","unstructured":"Chen JJ, Flanagan EP, Pittock SJ et al (2023) Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2023.02.013","journal-title":"Am J Ophthalmol"},{"key":"11737_CR77","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K et al (2014) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler J 20:501\u2013504. https:\/\/doi.org\/10.1177\/1352458513495938","journal-title":"Mult Scler J"},{"key":"11737_CR78","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1177\/1352458518811597","volume":"25","author":"LM Oliveira","year":"2019","unstructured":"Oliveira LM, Ap\u00f3stolos-Pereira SL, Pitombeira MS et al (2019) Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler J 25:1907\u20131914. https:\/\/doi.org\/10.1177\/1352458518811597","journal-title":"Mult Scler J"},{"key":"11737_CR79","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/JNNP-2017-315998","volume":"88","author":"JW Hyun","year":"2017","unstructured":"Hyun JW, Woodhall MR, Kim SH et al (2017) Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 88:811\u2013817. https:\/\/doi.org\/10.1136\/JNNP-2017-315998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11737_CR80","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F et al (2021) Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol 89:30\u201341. https:\/\/doi.org\/10.1002\/ana.25909","journal-title":"Ann Neurol"},{"key":"11737_CR81","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","volume":"75","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga AS, Majed M, Fryer J et al (2018) Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG\u2013associated disorders. JAMA Neurol 75:1355. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1814","journal-title":"JAMA Neurol"},{"key":"11737_CR82","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"11737_CR83","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/JAMANEUROL.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75:478\u2013487. https:\/\/doi.org\/10.1001\/JAMANEUROL.2017.4601","journal-title":"JAMA Neurol"},{"key":"11737_CR84","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95:e111\u2013e120. https:\/\/doi.org\/10.1212\/WNL.0000000000009758","journal-title":"Neurology"},{"key":"11737_CR85","doi-asserted-by":"publisher","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al (2020) Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord 44:102251. https:\/\/doi.org\/10.1016\/j.msard.2020.102251","DOI":"10.1016\/j.msard.2020.102251"},{"key":"11737_CR86","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1007\/s00415-020-10236-4","volume":"268","author":"Q Lu","year":"2021","unstructured":"Lu Q, Luo J, Hao H et al (2021) Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. J Neurol 268:4537\u20134548. https:\/\/doi.org\/10.1007\/s00415-020-10236-4","journal-title":"J Neurol"},{"key":"11737_CR87","doi-asserted-by":"publisher","unstructured":"Li S, Ren H, Xu Y, et al (2020) Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders. Neurol - Neuroimmunol Neuroinflammation 7:e705. https:\/\/doi.org\/10.1212\/NXI.0000000000000705","DOI":"10.1212\/NXI.0000000000000705"},{"key":"11737_CR88","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K et al (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"11737_CR89","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V et al (2017) Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 264:2003\u20132009. https:\/\/doi.org\/10.1007\/s00415-017-8590-0","journal-title":"J Neurol"},{"key":"11737_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","volume":"94","author":"G Spagni","year":"2023","unstructured":"Spagni G, Sun B, Monte G et al (2023) Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis Neuro-inflammation. J Neurol Neurosurg Psychiatry 94:62\u201369. https:\/\/doi.org\/10.1136\/jnnp-2022-330086","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11737_CR91","doi-asserted-by":"publisher","unstructured":"Nepal G, Kharel S, Coghlan MA, et al (2022) Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis. J Neuroimmunol 364:577812. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577812","DOI":"10.1016\/j.jneuroim.2022.577812"},{"key":"11737_CR92","doi-asserted-by":"publisher","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, et al (2022) Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease. Neurology 99:https:\/\/doi.org\/10.1212\/WNL.0000000000201260. https:\/\/doi.org\/10.1212\/WNL.0000000000201260","DOI":"10.1212\/WNL.0000000000201260 10.1212\/WNL.0000000000201260"},{"key":"11737_CR93","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.25648","volume":"87","author":"P Durozard","year":"2020","unstructured":"Durozard P, Rico A, Boutiere C et al (2020) Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 87:256\u2013266. https:\/\/doi.org\/10.1002\/ana.25648","journal-title":"Ann Neurol"},{"key":"11737_CR94","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","volume":"79","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Huda S, Hacohen Y et al (2022) Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 79:518. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0489","journal-title":"JAMA Neurol"},{"key":"11737_CR95","doi-asserted-by":"publisher","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, et al (2022) Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG\u2013Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurol - Neuroimmunol Neuroinflammation 9:e1100. https:\/\/doi.org\/10.1212\/NXI.0000000000001100","DOI":"10.1212\/NXI.0000000000001100"},{"key":"11737_CR96","doi-asserted-by":"publisher","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM (2021) Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord 48:102696. https:\/\/doi.org\/10.1016\/j.msard.2020.102696","DOI":"10.1016\/j.msard.2020.102696"},{"key":"11737_CR97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12974-021-02160-9","volume":"18","author":"J Havla","year":"2021","unstructured":"Havla J, Pakeerathan T, Schwake C et al (2021) Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation 18:121. https:\/\/doi.org\/10.1186\/s12974-021-02160-9","journal-title":"J Neuroinflammation"},{"key":"11737_CR98","doi-asserted-by":"publisher","unstructured":"Satukijchai C, Mariano R, Messina S, et al (2022) Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody\u2013Associated Disease in the United Kingdom. JAMA Netw Open 5:e2142780. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42780","DOI":"10.1001\/jamanetworkopen.2021.42780"},{"key":"11737_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejpn.2020.10.007","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Breu M, Wendel E-M et al (2020) E.U. paediatric MOG consortium consensus: Part 4\u2014outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:32\u201340. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.007","journal-title":"Eur J Paediatr Neurol"},{"key":"11737_CR100","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","volume":"266","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sep\u00falveda M, D\u2019Indy H et al (2019) Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol 266:806\u2013815. https:\/\/doi.org\/10.1007\/s00415-018-9160-9","journal-title":"J Neurol"},{"key":"11737_CR101","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/JAMAOPHTHALMOL.2020.4231","volume":"138","author":"SL Pineles","year":"2020","unstructured":"Pineles SL, Repka MX, Liu GT et al (2020) Assessment of pediatric optic neuritis visual acuity outcomes at 6\u00a0months. JAMA Ophthalmol 138:1253\u20131261. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2020.4231","journal-title":"JAMA Ophthalmol"},{"key":"11737_CR102","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728214.2021.1919082","volume":"26","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Marrodan M, Correale J (2021) Emerging drugs for the treatment of adult MOG-IgG-associated diseases. Expert Opin Emerg Drugs 26:75\u201378. https:\/\/doi.org\/10.1080\/14728214.2021.1919082","journal-title":"Expert Opin Emerg Drugs"},{"key":"11737_CR103","doi-asserted-by":"publisher","unstructured":"Gastaldi M, Foiadelli T, Greco G, et al (2022) Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. J Neurol Neurosurg Psychiatry 0:jnnp-2022\u2013330237. https:\/\/doi.org\/10.1136\/jnnp-2022-330237","DOI":"10.1136\/jnnp-2022-330237"},{"key":"11737_CR104","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","volume":"77","author":"AS Lopez-Chiriboga","year":"2020","unstructured":"Lopez-Chiriboga AS, Sechi E, Buciuc M et al (2020) Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin g-associated disorder. JAMA Neurol 77:1575. https:\/\/doi.org\/10.1001\/jamaneurol.2020.3115","journal-title":"JAMA Neurol"},{"key":"11737_CR105","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/ene.14746","volume":"28","author":"R Deschamps","year":"2021","unstructured":"Deschamps R, Pique J, Ayrignac X et al (2021) The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol 28:1659\u20131664. https:\/\/doi.org\/10.1111\/ene.14746","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11737-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:41:36Z","timestamp":1744198896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["11737"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11737-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Abdullah Al-Ani has no conflict of interest. Dr. John J Chen served as a consultant to UCB and Horizon. Dr. Fiona Costello has received advisory board or speaker fees from Alexion, Novartis, Accure Therapeutics, Frequency Therapeutics, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An ethics statement is not applicable because this article is based on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}